EUVIMEDEUVIMED entdecken
Crossref

Diagnostic performance of EUS-FNA for pancreatic lesions at tertiary centers in Iran without rapid on-site evaluation

Nadia Khalafi, Kourosh Kazemi, Zahra Beyzaei, Bita Geramizadeh

Transplant Immunology · 2026-08 · 97 · 102409

DOI: 10.1016/j.trim.2026.102409 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Immunology, 2026-08. Verfasst von Nadia Khalafi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Medical School of Shiraz University, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Liver Transplantation, Graft Rejection. Die Arbeit nennt 33 Literaturangaben. Gefördert von: Shiraz University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Complement component 4 degradation product (C4d) staining is a routine ancillary tool in diagnosing antibody-mediated rejection (AMR) in renal and cardiac allografts, but its role in liver transplantation (LT) remains controversial, especially given the infrequency of AMR. This study aimed to assess the positivity and pattern of C4d staining in ABO-compatible (ABO-C) LT allografts with varying degrees of rejection. MATERIALS AND METHODS In this retrospective cross-sectional study, we analyzed patients who received ABO-C LT between 2019 and 2021. We assessed the presence of AMR by evaluating C4d staining intensity and diffuseness using immunohistochemistry (IHC) on formalin-fixed paraffin-embedded liver tissue, which interpreted according to BANFF criteria. Donor-specific antibodies (DSAs), clinical, histological, and outcome data were also collected. RESULTS A total of 90 ABO-C LT recipients were included, with C4d data available for 47 subjects. Of these, 12 (25.5%) were C4d-positive based on BANFF criteria. C4d positivity was not significantly associated with mortality (P = 0.244), rejection (P = 0.310), or liver enzyme levels (i.e., AST, ALT, ALK; P = 0.958, 0.958, and 1.000, respectively). Additionally, the survival distributions for C4d + and C4d- groups were not significantly different (χ2 = 1.599, P = 0.206). Twelve subjects had concomitant DSA and C4d data, but all were C4d-negative, limiting our ability to assess the diagnostic value of the C4d+/DSA+ immunophenotype. DSAs did not show a significant relationship with mortality or rejection either. CONCLUSION The limited availability of paired C4d and DSAs data in this cohort precluded a meaningful evaluation of their combined role in diagnosing AMR in ABO-compatible liver transplantation. In the absence of cases with concurrent C4d and DSA positivity, our findings are inconclusive regarding their diagnostic utility. Larger, prospective studies with complete datasets are required to clarify the value of integrating C4d, DSA, and clinicopathological features in AMR diagnosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationGraft RejectionHumansFemaleMaleRetrospective StudiesMiddle AgedCross-Sectional StudiesComplement C4bAdultABO Blood-Group SystemIranTertiary Care CentersIsoantibodiesPeptide Fragments

Stichwörter der Autor:innen

ABO-compatible liver transplantationAntibody-mediated rejectionC4dDonor-specific antibodiesHLA antibodies

Substanzen

Complement C4bABO Blood-Group Systemcomplement C4dIsoantibodiesPeptide Fragments

Autor:innen und Institutionen

  • Department of Pathology, Medical School of Shiraz University, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Shiraz Transplant Centre, Abu-Ali-Sina Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Transplant Research Centre, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Department of Pathology, Medical School of Shiraz University, Shiraz University of Medical Sciences, Shiraz, Iran; Transplant Research Centre, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: ger…

Förderung

  • Shiraz University of Medical Sciences

Zitieren

APA

Khalafi, N., Kazemi, K., Beyzaei, Z., & Geramizadeh, B. (2026). Diagnostic performance of EUS-FNA for pancreatic lesions at tertiary centers in Iran without rapid on-site evaluation. Transplant Immunology, 97, 102409. https://doi.org/10.1016/j.trim.2026.102409

Vancouver

Khalafi N, Kazemi K, Beyzaei Z, Geramizadeh B. Diagnostic performance of EUS-FNA for pancreatic lesions at tertiary centers in Iran without rapid on-site evaluation. Transplant Immunology. 2026;97:102409. doi:10.1016/j.trim.2026.102409

BibTeX
@article{Khalafi2026,
  author = {Khalafi, Nadia and Kazemi, Kourosh and Beyzaei, Zahra and Geramizadeh, Bita},
  title = {Diagnostic performance of EUS-FNA for pancreatic lesions at tertiary centers in Iran without rapid on-site evaluation},
  journal = {Transplant Immunology},
  year = {2026},
  volume = {97},
  pages = {102409},
  doi = {10.1016/j.trim.2026.102409}
}
Kostenlos starten →